Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Operating Income: 2020-2024

Historic Operating Income for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to -$60.1 million.

  • Oncology Institute's Operating Income rose 4186.1% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.1 million, marking a year-over-year increase of 3524.43%. This contributed to the annual value of -$60.1 million for FY2024, which is 2194.29% up from last year.
  • Per Oncology Institute's latest filing, its Operating Income stood at -$60.1 million for FY2024, which was up 2194.29% from -$77.0 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Operating Income ranged from a high of -$8.2 million in FY2020 and a low of -$82.0 million during FY2022
  • For the 5-year period, Oncology Institute's Operating Income averaged around -$54.6 million, with its median value being -$60.1 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 45944.86% in 2021, then surged by 2194.29% in 2024.
  • Over the past 5 years, Oncology Institute's Operating Income (Annual) stood at -$8.2 million in 2020, then crashed by 459.45% to -$45.9 million in 2021, then plummeted by 78.71% to -$82.0 million in 2022, then increased by 6.02% to -$77.0 million in 2023, then grew by 21.94% to -$60.1 million in 2024.
  • Its last three reported values are -$60.1 million in FY2024, -$77.0 million for FY2023, and -$82.0 million during FY2022.